Biovest Takes 9 Percent Stake in MDxHealth | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that as part of its recent private placement, which brought in $11.7 million, investment firm Biovest has obtained a 9 percent stake in the company.

Biovest's president is Rudi Mariën, who is a co-founder and chairman of Innogenetics, a Belgium-based molecular diagnostics firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.